(PDF) Php35 - Amnog Early Benefit Assessment (Eba) and

Php35 - Amnog Early Benefit Assessment (Eba) and Market Penetration of New Drugs for Melanoma, Multiple Sclerosis and Diabetes Mellitus in Germany

Value in Health - United Kingdom

doi 10.1016/j.jval.2018.09.931

Full Text

Abstract

Available in full text

Categories

Occupational Health

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

Conditional Resolutions in the Amnog Early Benefit Assessment

Value in Health

Occupational Health

English

2.5 Years of Amnog in Germany – An Analysis of Benefit Assessment and Net Price Negotiation Trends

Value in Health

Occupational Health

English

Is the Proof of an Additional Benefit Under Amnog in Germany More Difficult for Certain Drugs Than for Other Ones?

Value in Health

Occupational Health

English

Php237 - Overview of German Amnog Dossiers With Price Analysis Before and After Early Benefit Assessment

Value in Health

Occupational Health

English

Php115 - Comparative Analysis of the Market Penetration of Personalised Medicine Drugs Under the Conditions of Amnog

Value in Health

Occupational Health

English

Inclusion and Consideration of Patient Preferences in Amnog Early Benefit Assessments

Value in Health

Occupational Health

English

Pcn309 - Diversity in Safety Data Analyses in German Amnog Benefit Assessments for Multiple Myeloma

Value in Health

Occupational Health

English

Php293 - Orphan Drugs in Germany - Lessons Learned From Amnog, Best and Worst Practices and Strategic Implications

Value in Health

Occupational Health

English

Pcn304 - Appropriate Comparator in German Amnog Benefit Assessments in Melanoma – A Dynamic Situation

Value in Health

Occupational Health

English